{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:10:21Z","timestamp":1761894621148},"reference-count":118,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.2515\/therapie:2007054","type":"journal-article","created":{"date-parts":[[2007,11,5]],"date-time":"2007-11-05T10:43:38Z","timestamp":1194259418000},"page":"293-310","source":"Crossref","is-referenced-by-count":20,"title":["Newly Approved and Promising Antidiabetic Agents"],"prefix":"10.1016","volume":"62","author":[{"given":"Murielle","family":"Combettes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Kargar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2007054_bb0005","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type-2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.2515\/therapie:2007054_bb0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00060793-199708000-00006","article-title":"Amylins physiology and its role in diabetes","volume":"4","author":"Young","year":"1997","journal-title":"Curr opin Endocrinol Diabetes"},{"issue":"3","key":"10.2515\/therapie:2007054_bb0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.regpep.2006.06.004","article-title":"Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC 187","volume":"137","author":"Gedulin","year":"2006","journal-title":"Regul Peptides"},{"issue":"11","key":"10.2515\/therapie:2007054_bb0020","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1210\/endo.142.11.8593","article-title":"Inhibition of central amylin signalling increases food intake and body adiposity in rats","volume":"142","author":"Rushing","year":"2001","journal-title":"Endocrinol"},{"issue":"1471","key":"10.2515\/therapie:2007054_bb0025","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1098\/rstb.2006.1858","article-title":"Pancreatic signals controlling food intake; insulin, glucagon and amylin","volume":"29","author":"Woods","year":"2006","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.2515\/therapie:2007054_bb0030","first-page":"E156","article-title":"Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity","volume":"267","author":"Pieber","year":"1994","journal-title":"Am J Physiol"},{"issue":"12","key":"10.2515\/therapie:2007054_bb0035","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Anti-obesity effects of the b-cell hormone amylin in DIO obese rats: effects on food intake, body weight, composition, energy expenditure and gene expression","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinol"},{"key":"10.2515\/therapie:2007054_bb0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/014572179902500310","article-title":"Clinical implications of amylin and amylin deficiency","volume":"25","author":"Kruger","year":"1999","journal-title":"Diabetes Educ"},{"key":"10.2515\/therapie:2007054_bb0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rate : comparisons with humans and rat amylin","volume":"37","author":"Young","year":"1996","journal-title":"Drug Dev Res"},{"key":"10.2515\/therapie:2007054_bb0050","doi-asserted-by":"crossref","first-page":"105S","DOI":"10.1177\/0145721706288S246","article-title":"Amylin replacement therapy in patients with insulin-requiring type 2 diabetes","volume":"32","author":"Owen","year":"2006","journal-title":"Diabetes Educator"},{"key":"10.2515\/therapie:2007054_bb0055","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/0145721706294003","article-title":"Update of the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide","volume":"32","author":"Odegard","year":"2006","journal-title":"Diabetes Educ"},{"issue":"8","key":"10.2515\/therapie:2007054_bb0060","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"issue":"1","key":"10.2515\/therapie:2007054_bb0065","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.2515\/therapie:2007054_bb0070","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","article-title":"Continuous subcutaneous infusion of glucagon-like peptide 1 loweres plasma glucose and reduces appetite in type 2 diabetic patients","volume":"22","author":"Toft-Nielsen","year":"1999","journal-title":"Diabetes Care"},{"issue":"9309","key":"10.2515\/therapie:2007054_bb0075","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagonlike peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type-2 Diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.2515\/therapie:2007054_bb0080","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0085","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/diabetes.50.7.1562","article-title":"GLP-1 and Exendin-4 stimulate betacell mass neogenesis in STZ-treated newborn rats resulting in persistantly improved glucose homeostasis at adult age","volume":"50","author":"Tourrel","year":"2001","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0090","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","article-title":"Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats","volume":"143","author":"Farilla","year":"2002","journal-title":"Endocrinology"},{"key":"10.2515\/therapie:2007054_bb0095","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition od DPPIV with a sitagliptin analog preserves pancreatic \u03b2-cell mass and function in a rodent model of type 2 diabetes","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0100","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.coph.2006.08.003","article-title":"GLP-1 and type 2 diabetes: physiology and new clinical advances","volume":"6","author":"Combettes","year":"2006","journal-title":"Cur Opin In Pharmacol"},{"key":"10.2515\/therapie:2007054_bb0105","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.2515\/therapie:2007054_bb0110","first-page":"33","article-title":"Type 2 diabetes-Therapy with dipeptidyl peptidase IV inhibitors","volume":"2005","author":"Demuth","year":"1751","journal-title":"Biochim Biophys Act"},{"key":"10.2515\/therapie:2007054_bb0115","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","article-title":"Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon like peptide-1 in the anaesthetised pig","volume":"48","author":"Plamboeck","year":"2005","journal-title":"Diabetologia"},{"key":"10.2515\/therapie:2007054_bb0120","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0014-5793(98)00502-X","article-title":"DPPIV, CD26 is involved in regulation of DNA synthesis in human keratinocytes","volume":"428","author":"Reinhold","year":"1998","journal-title":"FEBS Letters"},{"key":"10.2515\/therapie:2007054_bb0125","doi-asserted-by":"crossref","first-page":"R1449","DOI":"10.1152\/ajpregu.2000.279.4.R1449","article-title":"Portal GLP-1 administration in rats augments the insulin response to glucose by neuronal mechanisms","volume":"279","author":"Balkan","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.2515\/therapie:2007054_bb0130","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/diabetes.50.8.1720","article-title":"Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor","volume":"50","author":"Burcelin","year":"2001","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0135","doi-asserted-by":"crossref","first-page":"G806","DOI":"10.1152\/ajpgi.00121.2005","article-title":"Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors","volume":"289","author":"Dardevet","year":"2005","journal-title":"Am J Physiol gastrointest Liver Physiol"},{"key":"10.2515\/therapie:2007054_bb0140","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00125-005-1705-7","article-title":"Glucagon-like peptide-1 mediates the therapeutic actions of DPPIV inhibitors","volume":"48","author":"Holst","year":"2005","journal-title":"Diabetologia"},{"key":"10.2515\/therapie:2007054_bb0145","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00125-005-1709-3","article-title":"Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counterregulatory hormones","volume":"48","author":"Ionut","year":"2005","journal-title":"Diabetologia"},{"key":"10.2515\/therapie:2007054_bb0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"AmJ Health Syst Pharm"},{"key":"10.2515\/therapie:2007054_bb0155","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.2515\/therapie:2007054_bb0160","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.2515\/therapie:2007054_bb0165","first-page":"471","article-title":"Diabetes Care","volume":"29","author":"Kendall","year":"2006"},{"key":"10.2515\/therapie:2007054_bb0170","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.2515\/therapie:2007054_bb0175","first-page":"P19","article-title":"Unique study design: evaluation of the effect of dose titration on dose-limiting nausea (abstract)","volume":"71","author":"Fineman","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie:2007054_bb0180","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"10.2515\/therapie:2007054_bb0185","first-page":"1487","article-title":"Diabetes Care","volume":"30","author":"Kim","year":"2007"},{"issue":"6","key":"10.2515\/therapie:2007054_bb0190","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc06-2593","article-title":"Liraglutide, a long-acting human GLP-1 Analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with Type 2 diabetes mellitus","volume":"30","author":"Vilsboll","year":"2007","journal-title":"Diabetes Care"},{"key":"10.2515\/therapie:2007054_bb0195","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1016\/j.bmcl.2004.06.066","article-title":"Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog","volume":"14","author":"Leger","year":"2004","journal-title":"Bio Org Med Chem Lett"},{"issue":"6","key":"10.2515\/therapie:2007054_bb0200","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl peptisase-4 inhibition and the treatment of type 2 diabetes : preclinical biology and mechanism of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.2515\/therapie:2007054_bb0205","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc07-0233","article-title":"DPP4 inhibitors \u2013 Clinical data and clinical implications","volume":"30","author":"Ahren","year":"2007","journal-title":"Diabetes Care"},{"issue":"11","key":"10.2515\/therapie:2007054_bb0210","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"issue":"12","key":"10.2515\/therapie:2007054_bb0215","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"issue":"12","key":"10.2515\/therapie:2007054_bb0220","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"issue":"10","key":"10.2515\/therapie:2007054_bb0225","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Ther"},{"issue":"1","key":"10.2515\/therapie:2007054_bb0230","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.diabres.2006.12.009","article-title":"Efficacy and tolerability in drugna\u00efve patients with type 2 diabetes","volume":"76","author":"Pi-Sunyer","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"issue":"suppl 1","key":"10.2515\/therapie:2007054_bb0235","first-page":"A29","article-title":"Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes","volume":"55","author":"Dejager","year":"2006","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.2515\/therapie:2007054_bb0240","first-page":"486","article-title":"Efficacy of vildagliptin combined with pioglitazone in patients with type 2 diabetes","volume":"49","author":"Rosenstock","year":"2006","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.2515\/therapie:2007054_bb0245","first-page":"A29","article-title":"Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes","volume":"55","author":"Garber","year":"2006","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.2515\/therapie:2007054_bb0250","first-page":"A111","article-title":"Vildagliptin as add-on to insulin in patients with type 2 diabetes","volume":"55","author":"Fonseca","year":"2006","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0255","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","article-title":"Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes","volume":"54","author":"Lankas","year":"2005","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0260","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and tolerability of the DPPIV inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"issue":"suppl.1","key":"10.2515\/therapie:2007054_bb0265","first-page":"A113","article-title":"Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes","volume":"55","author":"Nathwani","year":"2006","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0270","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of DPPIV with a sitagliptin analog preserves pancreatic \u03b2-cell mass and function in a rodent model of type 2 diabetes","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0275","first-page":"A66","article-title":"The DPPIV inhibitor vildagliptin increases pancreatic betacell neogenesis and decreases apoptosis","volume":"54","author":"Duttaroy","year":"2005","journal-title":"Diabetes"},{"issue":"Supl. 1","key":"10.2515\/therapie:2007054_bb0280","first-page":"597-P","article-title":"S 40010, a potent DPPIV inhibitor, improves long-term glycemic control in db\/db mice and increases pancreatic b-cell mass and neogenesis","volume":"56","author":"Combettes","year":"2007","journal-title":"Diabetes"},{"issue":"6","key":"10.2515\/therapie:2007054_bb0285","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1463-1326.2005.00539.x","article-title":"Improved glycemic control with DPPIV inhibition in patients with type 2 diabetes: vildagliptin (LAF 237) dose response","volume":"7","author":"Ristic","year":"2005","journal-title":"Diabetes Obes Metab"},{"issue":"supl.1","key":"10.2515\/therapie:2007054_bb0290","first-page":"A29","article-title":"Vildagliptin suppresses endogenous glucose production (EGP) and increases beta cell function after single dose administration in type 2 diabetic (T2D) patients","volume":"55","author":"Balas","year":"2006","journal-title":"Diabetes"},{"issue":"supl. 1","key":"10.2515\/therapie:2007054_bb0295","first-page":"A462","article-title":"Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24weeks in patients with type 2 diabetes (T2DM)","volume":"55","author":"Aschner","year":"2006","journal-title":"Diabetes"},{"issue":"supl.1","key":"10.2515\/therapie:2007054_bb0300","first-page":"A462","article-title":"Sitagliptin monotherapy improved glycemic control and beta-cell function after 18weeks in patients with type 2 diabetes (T2DM)","volume":"55","author":"Raz","year":"2006","journal-title":"Diabetes"},{"issue":"3","key":"10.2515\/therapie:2007054_bb0305","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1464-5491.2006.02071.x","article-title":"Incretins and others peptides in the treatment of diabetes","volume":"24","author":"Todd","year":"2007","journal-title":"Diabetes Med"},{"issue":"4","key":"10.2515\/therapie:2007054_bb0310","first-page":"319","article-title":"Inhibitors of 11b-hydroxysteroid deshydrogenase type 1 for the treatment of metabolic syndrome","volume":"7","author":"Wang","year":"2006","journal-title":"Cur Opin Invest Drugs"},{"issue":"11","key":"10.2515\/therapie:2007054_bb0315","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1210\/en.2003-0344","article-title":"Selective inhibition of 11b-hydroxysteroid deshydrogenase type 1 improves heapatic insulin sensitivity in hyperglycemic mice","volume":"144","author":"Alberts","year":"2003","journal-title":"Endocrinol"},{"issue":"11","key":"10.2515\/therapie:2007054_bb0320","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/s00125-002-0959-6","article-title":"Selective inhibition of 11bhydroxysteroid deshydrogenase type 1 decreases blood glucose concentrations in hyperglycemic mice","volume":"45","author":"Alberts","year":"2002","journal-title":"Diabetologia"},{"key":"10.2515\/therapie:2007054_bb0325","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1084\/jem.20050119","article-title":"11\u03b2-HSD-1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice","volume":"4","author":"Hermanowski-Vosatka","year":"2005","journal-title":"J Exp Med"},{"key":"10.2515\/therapie:2007054_bb0330","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0140-6736(96)11222-8","article-title":"Does central obesity reflect, Cushing\u2019s disease of the omentum\u201d?","volume":"349","author":"Bujalska","year":"1997","journal-title":"Lancet"},{"key":"10.2515\/therapie:2007054_bb0335","first-page":"3330","article-title":"Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11b-hydroxysteroid deshydrogenase type 1 activity","volume":"87","author":"Rask","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.2515\/therapie:2007054_bb0340","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2362.2005.01552.x","article-title":"Increased expression of 11\u03b2-HSD-1 in type 2 diabetic myotubes","volume":"35","author":"Abdallah","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"10.2515\/therapie:2007054_bb0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/187153006778250000","article-title":"Type 1 11b-hydroxysteroid deshydrogenase as universal drug target in metabolic diseases?","volume":"6","author":"Opperman","year":"2006","journal-title":"Endo Metab& Immune disorders \u2013 Drugs targets"},{"issue":"2","key":"10.2515\/therapie:2007054_bb0350","first-page":"379","article-title":"RU-486 prevents the acute effects of cortisol on glucose and leucine metabolism","volume":"80","author":"Garrel","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.2515\/therapie:2007054_bb0355","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.ijo.0800479","article-title":"RU-486 ameliorates diabetes but does not correct deficient beta-adrenergic signalling in adipocytes from mature C57BL\/6J-ob\/ob mice","volume":"21","author":"Gettys","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.2515\/therapie:2007054_bb0360","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bmcl.2006.10.003","article-title":"Discovery of novel phosphoruscontaining steroids as selective glucocorticoid receptor antagonist","volume":"17","author":"Jiang","year":"2007","journal-title":"Biorg Medicinal Chemistry Let"},{"key":"10.2515\/therapie:2007054_bb0365","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/jm0400045","article-title":"Liver-specific glucocorticoid receptor antagonists: a novel treatment for type 2 diabetes","volume":"47","author":"Von Geldern","year":"2004","journal-title":"J Med Chem"},{"issue":"1","key":"10.2515\/therapie:2007054_bb0370","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/jpet.104.081257","article-title":"Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes","volume":"314","author":"Jacobson","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"10.2515\/therapie:2007054_bb0375","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1021\/jm050205o","article-title":"Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators","volume":"48","author":"Link","year":"2005","journal-title":"J Med Chem"},{"issue":"3","key":"10.2515\/therapie:2007054_bb0380","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.metabol.2006.10.021","article-title":"Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance","volume":"56","author":"Zinker","year":"2007","journal-title":"Metabolism"},{"key":"10.2515\/therapie:2007054_bb0385","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2337\/diabetes.47.3.307","article-title":"Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities","volume":"47","author":"Matschinsky","year":"1998","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0390","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/dmrr.217","article-title":"Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis","volume":"17","author":"Radziuk","year":"2001","journal-title":"Diabetes Metab Res Rev"},{"key":"10.2515\/therapie:2007054_bb0395","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0065-2571(92)90013-P","article-title":"The regulatory protein of liver glucokinase","volume":"32","author":"Van Schaftingen","year":"1992","journal-title":"Adv Enzyme Regul"},{"key":"10.2515\/therapie:2007054_bb0400","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1042\/bj3210239","article-title":"Investigation on the mechanism by which fructose, hexitols and other compounds regulate the translocation of glucokinase in rat hepatocytes","volume":"321","author":"Niculescu","year":"1997","journal-title":"Biochem J"},{"key":"10.2515\/therapie:2007054_bb0405","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2337\/diabetes.54.7.1949","article-title":"Dual role of phosphofructokinase-2\/fructose bisphosphatase-2 in regulating the compartmentation and expression of glucokinase in hepatocytes","volume":"54","author":"Payne","year":"2005","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0410","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nature01825","article-title":"BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis","volume":"424","author":"Danial","year":"2003","journal-title":"Nature"},{"key":"10.2515\/therapie:2007054_bb0415","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/humu.10277","article-title":"Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy","volume":"22","author":"Gloyn","year":"2003","journal-title":"Hum Mutat"},{"key":"10.2515\/therapie:2007054_bb0420","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ecl.2006.02.009","article-title":"Genetic basis of maturity-onset diabetes of the young","volume":"35","author":"Vaxillaire","year":"2006","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.2515\/therapie:2007054_bb0425","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.mej.0000228437.02534.85","article-title":"Neonatal diabetes mellitus: A rare but important diagnosis in the critically ill infant","volume":"13","author":"Woolley","year":"2006","journal-title":"Eur J Emerg Med"},{"key":"10.2515\/therapie:2007054_bb0430","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ncpendmet0368","article-title":"Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates","volume":"3","author":"De Leon","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.2515\/therapie:2007054_bb0435","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1042\/BST0330371","article-title":"Small molecule glucokinase activators as novel anti-diabetic agents","volume":"33","author":"Leighton","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"10.2515\/therapie:2007054_bb0440","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1210\/en.2005-0377","article-title":"A novel glucokinase activator modulates pancreatic islet and hepatocyte function","volume":"146","author":"Grimsby","year":"2005","journal-title":"Endocrinology"},{"key":"10.2515\/therapie:2007054_bb0445","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diabetes.53.3.535","article-title":"Stimulation of hepatocyte glucose metabolism by novel small molcecule glucokinase activators","volume":"53","author":"Brocklehurst","year":"2004","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0450","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.bmcl.2005.01.087","article-title":"Discovery, synthesis and biological evaluation of novel glucokinase activators","volume":"15","author":"McKerrecher","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.2515\/therapie:2007054_bb0455","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.bmcl.2006.02.022","article-title":"Design of a potent, soluble glucokinase activator with excellent in vivo efficacy","volume":"16","author":"McKerrecher","year":"2006","journal-title":"Bio org Med Chem Lett"},{"key":"10.2515\/therapie:2007054_bb0460","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1126\/science.1084073","article-title":"Allosteric activators of glucokinase: potential role in diabetes therapy","volume":"301","author":"Dvorozniak","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.2515\/therapie:2007054_bb0465","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2337\/db07-0026","article-title":"Glucose-dependent modulation of insulin secretion and intracellular calcium by GKA50 \u2013 a glucokinase activator","volume":"56","author":"Jonhson","year":"2007","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0470","doi-asserted-by":"crossref","first-page":"37668","DOI":"10.1074\/jbc.M605186200","article-title":"An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism","volume":"281","author":"Futamura","year":"2006","journal-title":"J Biol Chem"},{"key":"10.2515\/therapie:2007054_bb0475","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1210\/en.2005-0689","article-title":"Tweaking the glucose sensor: adjusting glucokinase activity with activator compounds","volume":"146","author":"Printz","year":"2005","journal-title":"Endocrinology"},{"key":"10.2515\/therapie:2007054_bb0480","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI115997","article-title":"Increased rate of gluconeogenesis in type 2 diabetes mellitus. A 13C nuclear magnetic resonance study","volume":"90","author":"Magnusson","year":"1992","journal-title":"J Clin Invest"},{"key":"10.2515\/therapie:2007054_bb0485","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1517\/13543784.10.3.439","article-title":"Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus","volume":"10","author":"Treadway","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.2515\/therapie:2007054_bb0490","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1021\/jm980264k","article-title":"Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase","volume":"41","author":"Hoover","year":"1998","journal-title":"J Med Chem"},{"key":"10.2515\/therapie:2007054_bb0495","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1073\/pnas.95.4.1776","article-title":"Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo","volume":"95","author":"Martin","year":"1998","journal-title":"PNAS"},{"key":"10.2515\/therapie:2007054_bb0500","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/BF00281991","article-title":"Glucagon physiology and pathophysiology in the light of new advances","volume":"28","author":"Unger","year":"1985","journal-title":"Diabetologia"},{"key":"10.2515\/therapie:2007054_bb0505","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2337\/diabetes.53.2.410","article-title":"Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db\/db mice","volume":"53","author":"Liang","year":"2004","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0510","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/BF00400461","article-title":"Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats","volume":"37","author":"Brand","year":"1994","journal-title":"Diabetologia"},{"key":"10.2515\/therapie:2007054_bb0520","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1073\/pnas.84.12.4083","article-title":"Synthetic peptide antagonists of glucagon","volume":"84","author":"Unson","year":"1987","journal-title":"PNAS"},{"key":"10.2515\/therapie:2007054_bb0525","doi-asserted-by":"crossref","first-page":"12506","DOI":"10.1074\/jbc.M600127200","article-title":"Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist","volume":"281","author":"Pan","year":"2006","journal-title":"JBC"},{"key":"10.2515\/therapie:2007054_bb0530","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s001250100006","article-title":"Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans","volume":"44","author":"Petersen","year":"2001","journal-title":"Diabetologia"},{"key":"10.2515\/therapie:2007054_bb0535","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1006\/geno.1995.1085","article-title":"Human fructose-1,6-bisphosphatase gene (FBP1): exon\u2013intron organization, localization to chromosome bands 9q22.2\u2013q22.3, and mutation screening in subjects with fructose-1,6-bisphosphatase deficiency","volume":"27","author":"El-Maghrabi","year":"1995","journal-title":"Genomics"},{"key":"10.2515\/therapie:2007054_bb0540","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1086\/514875","article-title":"Identification of genetic mutations in Japanese patients with fructose-1,6-biphosphatase deficiency","volume":"61","author":"Kikawa","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.2515\/therapie:2007054_bb0545","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1023\/A:1005489617843","article-title":"Novel mutations in patients with fructose-1,6-bisphosphatase deficiency","volume":"22","author":"Herzog","year":"1999","journal-title":"J Inherit Metab Dis"},{"key":"10.2515\/therapie:2007054_bb0550","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(70)92474-8","article-title":"Fasting hypoglycaemia and metabolic acidosis associated with deficiency of hepatic fructose-1,6-diphosphatase activity","volume":"2","author":"Baker","year":"1970","journal-title":"Lancet"},{"key":"10.2515\/therapie:2007054_bb0555","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/mgme.2000.2983","article-title":"Fructose-1,6-diphosphatase deficiency and glyceroluria: one possible etiology for GIS","volume":"69","author":"Beatty","year":"2000","journal-title":"Mol Genet Metab"},{"key":"10.2515\/therapie:2007054_bb0560","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1073\/pnas.78.5.2861","article-title":"Inhibition of Fructose-1, 6-bisphosphatase by Fructose 2,6-bisphosphate","volume":"78","author":"Van Schaftingen","year":"1981","journal-title":"PNAS"},{"key":"10.2515\/therapie:2007054_bb0565","first-page":"45","article-title":"Mechanism of action of fructose 1,6-bisphosphatase","volume":"53","author":"Benkovic","year":"1982","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"10.2515\/therapie:2007054_bb0570","doi-asserted-by":"crossref","first-page":"51176","DOI":"10.1074\/jbc.M308396200","article-title":"Inhibition of fructose-1,6-bisphosphatase by a new class of allosteric effectors","volume":"278","author":"Choe","year":"2003","journal-title":"JBC"},{"key":"10.2515\/therapie:2007054_bb0575","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2337\/db05-1443","article-title":"Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker Diabetic Fatty rats","volume":"55","author":"Van Poelje","year":"2006","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2007054_bb0580","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.2174\/0929867043364360","article-title":"Glucose transporter and Na+\/glucose cotransporter as molecular targets of anti-diabetic drugs","volume":"11","author":"Asana","year":"2004","journal-title":"Cur Med Chem"},{"key":"10.2515\/therapie:2007054_bb0585","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","article-title":"a novel selective inhibitor of lowaffinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level","volume":"320","author":"Katsuno","year":"2007","journal-title":"J Pharmac Exp Therap"},{"key":"10.2515\/therapie:2007054_bb0590","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/j.lfs.2004.09.038","article-title":"Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats","volume":"76","author":"Ueta","year":"2005","journal-title":"Life Sc"},{"key":"10.2515\/therapie:2007054_bb0595","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00439-002-0820-5","article-title":"Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose co-transporter (SGLT2)","volume":"111","author":"Van den Heuvel","year":"2002","journal-title":"Human Genet"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:07:17Z","timestamp":1554260837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716304930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0040595716304930"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2007054","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}